**Table 3, Supplementary Digital Content 4.** TEAEs reported for ≥2% of patients during the treatment period

|  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| **TEAEs, n (%)** | **PBO(n = 66)** | **LIN IR290 μg(n = 66)** | **LIN DR130 μg(n = 67)** | **LIN DR1100 μg(n = 67)** | **LIN DR1300 μg(n = 67)** | **MD-724630 μg(n = 67)** | **MD-7246100 μg(n = 66)** | **MD-7246300 μg(n = 66)** |
| Any TEAE | 20 (30.3) | 27 (40.9) | 23 (34.3) | 23 (34.3) | 28 (41.8) | 15 (22.4) | 15 (22.7) | 20 (30.3) |
| Diarrhea | 1 (1.5) | 9 (13.6) | 2 (3.0) | 5 (7.5) | 7 (10.4) | 0 | 1 (1.5) | 2 (3.0) |
| Abdominal pain, upper | 0 | 2 (3.0) | 0 | 0 | 0 | 0 | 0 | 0 |
| Abdominal pain | 0 | 2 (3.0) | 0 | 1 (1.5) | 0 | 0 | 1 (1.5) | 1 (1.5) |
| Hemorrhoids | 1 (1.5) | 2 (3.0) | 0 | 0 | 0 | 0 | 0 | 0 |
| Hypertension | 0 | 2 (3.0) | 0 | 0 | 0 | 0 | 0 | 1 (1.5) |
| Nasopharyngitis | 3 (4.5) | 2 (3.0) | 2 (3.0) | 1 (1.5) | 0 | 1 (1.5) | 1 (1.5) | 1 (1.5) |
| Headache | 0 | 1 (1.5) | 2 (3.0) | 4 (6.0) | 1 (1.5) | 0 | 0 | 0 |
| URTI | 0 | 1 (1.5) | 0 | 0 | 0 | 0 | 1 (1.5) | 2 (3.0) |
| Nausea | 1 (1.5) | 1 (1.5) | 2 (3.0) | 3 (4.5) | 2 (3.0) | 0 | 1 (1.5) | 0 |
| Abdominal distension | 0 | 0 | 1 (1.5) | 2 (3.0) | 3 (4.5) | 0 | 1 (1.5) | 2 (3.0) |
| Anemia | 1 (1.5) | 0 | 2 (3.0) | 0 | 1 (1.5) | 0 | 0 | 3 (4.5) |
| DM inadequate control | 2 (3.0) | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Dyspepsia | 2 (3.0) | 0 | 0 | 1 (1.5) | 0 | 0 | 0 | 0 |
| Flatulence | 1 (1.5) | 0 | 0 | 2 (3.0) | 0 | 2 (3.0) | 1 (1.5) | 0 |
| Hypokalemia | 0 | 0 | 0 | 0 | 2 (3.0) | 0 | 0 | 0 |
| Pneumonia | 2 (3.0) | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Sinusitis | 0 | 0 | 1 (1.5) | 0 | 3 (4.5) | 1 (1.5) | 0 | 1 (1.5) |
| Weight gain | 0 | 0 | 0 | 0 | 0 | 0 | 2 (3.0) | 0 |

DM, diabetes mellitus; DR1, delayed-release formulation 1; IR, immediate-release formulation; LIN, linaclotide; PBO, placebo; TEAE, treatment-emergent adverse event; URTI, upper respiratory tract infection.